vs
Side-by-side financial comparison of Getty Images Holdings, Inc. (GETY) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Getty Images Holdings, Inc. is the larger business by last-quarter revenue ($282.3M vs $281.3M, roughly 1.0× Guardant Health, Inc.). Getty Images Holdings, Inc. runs the higher net margin — -32.2% vs -45.7%, a 13.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 14.1%). Getty Images Holdings, Inc. produced more free cash flow last quarter ($7.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 12.7%).
Getty Images Holdings, Inc. is a visual media company and supplier of stock images, editorial photography, video, and music for businesses and consumers, with a library of over 477 million assets. It targets three markets—creative professionals, the media, and corporate.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GETY vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $282.3M | $281.3M |
| Net Profit | $-90.9M | $-128.5M |
| Gross Margin | 74.8% | 64.6% |
| Operating Margin | -8.5% | -43.0% |
| Net Margin | -32.2% | -45.7% |
| Revenue YoY | 14.1% | 39.4% |
| Net Profit YoY | -467.6% | -15.8% |
| EPS (diluted) | $-0.22 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $282.3M | $281.3M | ||
| Q3 25 | $240.0M | $265.2M | ||
| Q2 25 | $234.9M | $232.1M | ||
| Q1 25 | $224.1M | $203.5M | ||
| Q4 24 | $247.3M | $201.8M | ||
| Q3 24 | $240.5M | $191.5M | ||
| Q2 24 | $229.1M | $177.2M | ||
| Q1 24 | $222.3M | $168.5M |
| Q4 25 | $-90.9M | $-128.5M | ||
| Q3 25 | $21.6M | $-92.7M | ||
| Q2 25 | $-34.4M | $-99.9M | ||
| Q1 25 | $-102.6M | $-95.2M | ||
| Q4 24 | $24.7M | $-111.0M | ||
| Q3 24 | $-2.5M | $-107.8M | ||
| Q2 24 | $3.7M | $-102.6M | ||
| Q1 24 | $13.6M | $-115.0M |
| Q4 25 | 74.8% | 64.6% | ||
| Q3 25 | 73.2% | 64.7% | ||
| Q2 25 | 72.1% | 65.0% | ||
| Q1 25 | 73.1% | 63.3% | ||
| Q4 24 | 73.5% | 61.6% | ||
| Q3 24 | 73.4% | 61.1% | ||
| Q2 24 | 72.5% | 59.1% | ||
| Q1 24 | 72.9% | 61.2% |
| Q4 25 | -8.5% | -43.0% | ||
| Q3 25 | 18.8% | -37.3% | ||
| Q2 25 | 15.1% | -45.9% | ||
| Q1 25 | 12.2% | -54.6% | ||
| Q4 24 | 14.5% | -62.4% | ||
| Q3 24 | 23.9% | -61.3% | ||
| Q2 24 | 20.3% | -56.8% | ||
| Q1 24 | 18.5% | -59.2% |
| Q4 25 | -32.2% | -45.7% | ||
| Q3 25 | 9.0% | -35.0% | ||
| Q2 25 | -14.6% | -43.0% | ||
| Q1 25 | -45.8% | -46.8% | ||
| Q4 24 | 10.0% | -55.0% | ||
| Q3 24 | -1.1% | -56.3% | ||
| Q2 24 | 1.6% | -57.9% | ||
| Q1 24 | 6.1% | -68.2% |
| Q4 25 | $-0.22 | $-1.01 | ||
| Q3 25 | $0.05 | $-0.74 | ||
| Q2 25 | $-0.08 | $-0.80 | ||
| Q1 25 | $-0.25 | $-0.77 | ||
| Q4 24 | $0.07 | $-0.90 | ||
| Q3 24 | $-0.01 | $-0.88 | ||
| Q2 24 | $0.01 | $-0.84 | ||
| Q1 24 | $0.03 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.2M | $378.2M |
| Total DebtLower is stronger | $1.3B | $1.5B |
| Stockholders' EquityBook value | $552.5M | $-99.3M |
| Total Assets | $3.2B | $2.0B |
| Debt / EquityLower = less leverage | 2.30× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.2M | $378.2M | ||
| Q3 25 | $109.5M | $580.0M | ||
| Q2 25 | $110.3M | $629.1M | ||
| Q1 25 | $114.6M | $698.6M | ||
| Q4 24 | $121.2M | $525.5M | ||
| Q3 24 | $109.9M | $585.0M | ||
| Q2 24 | $121.7M | $933.7M | ||
| Q1 24 | $134.2M | $1.0B |
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $552.5M | $-99.3M | ||
| Q3 25 | $634.6M | $-354.5M | ||
| Q2 25 | $611.2M | $-305.5M | ||
| Q1 25 | $593.0M | $-250.8M | ||
| Q4 24 | $670.2M | $-139.6M | ||
| Q3 24 | $683.4M | $-60.1M | ||
| Q2 24 | $654.0M | $-1.6M | ||
| Q1 24 | $640.8M | $68.3M |
| Q4 25 | $3.2B | $2.0B | ||
| Q3 25 | $2.6B | $1.3B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.6B | $1.5B | ||
| Q3 24 | $2.6B | $1.5B | ||
| Q2 24 | $2.6B | $1.6B | ||
| Q1 24 | $2.6B | $1.7B |
| Q4 25 | 2.30× | — | ||
| Q3 25 | 2.11× | — | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 2.21× | — | ||
| Q4 24 | 1.96× | — | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 2.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.6M | $-26.4M |
| Free Cash FlowOCF − Capex | $7.7M | $-54.2M |
| FCF MarginFCF / Revenue | 2.7% | -19.3% |
| Capex IntensityCapex / Revenue | 4.6% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.7M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.6M | $-26.4M | ||
| Q3 25 | $22.6M | $-35.4M | ||
| Q2 25 | $6.5M | $-60.3M | ||
| Q1 25 | $15.4M | $-62.7M | ||
| Q4 24 | $39.7M | $-64.5M | ||
| Q3 24 | $10.7M | $-51.1M | ||
| Q2 24 | $46.4M | $-94.0M | ||
| Q1 24 | $21.5M | $-30.3M |
| Q4 25 | $7.7M | $-54.2M | ||
| Q3 25 | $7.9M | $-45.8M | ||
| Q2 25 | $-9.6M | $-65.9M | ||
| Q1 25 | $-322.0K | $-67.1M | ||
| Q4 24 | $24.6M | $-83.4M | ||
| Q3 24 | $-1.8M | $-55.3M | ||
| Q2 24 | $31.1M | $-99.1M | ||
| Q1 24 | $7.1M | $-37.2M |
| Q4 25 | 2.7% | -19.3% | ||
| Q3 25 | 3.3% | -17.3% | ||
| Q2 25 | -4.1% | -28.4% | ||
| Q1 25 | -0.1% | -33.0% | ||
| Q4 24 | 9.9% | -41.3% | ||
| Q3 24 | -0.8% | -28.9% | ||
| Q2 24 | 13.6% | -55.9% | ||
| Q1 24 | 3.2% | -22.1% |
| Q4 25 | 4.6% | 9.9% | ||
| Q3 25 | 6.1% | 3.9% | ||
| Q2 25 | 6.9% | 2.4% | ||
| Q1 25 | 7.0% | 2.2% | ||
| Q4 24 | 6.1% | 9.4% | ||
| Q3 24 | 5.2% | 2.2% | ||
| Q2 24 | 6.7% | 2.9% | ||
| Q1 24 | 6.5% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 12.59× | — | ||
| Q1 24 | 1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GETY
| Creative | $149.0M | 53% |
| Editorial | $109.4M | 39% |
| Other | $23.9M | 8% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
